CVP mentors

David Dahan is a strategic advisor, with a particular focus on investment management of real assets, business growth, transformational change and post-acquisition integration.  

His experience spans over 23 years in financial services. Earlier in his career, he held a variety of corporate and business strategy roles, in which David worked with global Boards and Executive teams. Most recently, David was Managing Director of Aviva Investors' activities in infrastructure and structured finance assets, as well as co-head of Alternative Income Solutions. He was previously part of the Aviva Investors real estate executive committee with a range of responsibilities during his tenure; he led strategic and corporate development, he created and grew a number of new businesses and has led real-asset based income strategies, private equity, listed real estate securities, infrastructure and structured finance investment businesses and teams.   

David has studied and worked in France, the US and the UK. He holds a BA in Political Economy of Industrial Societies from the University of California, Berkeley, as well as an MBA from Cambridge Judge Business School. He is also a fellow of the Chartered Institute of Management Accountants.

Jane has over 15 years' experience in business development gained from roles in both biotech and pharma. Since joining F-star in late 2011 Jane has led a series of significant and innovative transactions with BMS, AbbVie, Denali and Merck (EMD Serono) raising almost $200M in non-dilutive financing and advancing F-star’s drug pipeline. By establishing asset-centric-vehicles as well as more traditional licensing, F-star has been able to realise the value of its individual assets through flexible deal structuring. As well as business development, Jane is responsible for transactional legal matters, IP and Communications at F-star. Earlier this year she was identified by Labiotech as one of the 15 Women Leading in European Biotech. 

Prior to F-star, she held business development positions at Cellzome and Cambridge Antibody Technology (CAT). At Cellzome she led two significant transactions with GSK; Cellzome was subsequently acquired by GSK in 2012. During her time at CAT she led negotiations on multiple significant transactions, subsequently continuing this work within AstraZeneca following the acquisition of CAT. 

She has a first class degree, a PhD and an MBA from the University of Cambridge and spent the first part of her career within the agrochemical industry. She is Vice-Chair of the Sir Richard Stapley Educational Trust, a member of the University of Cambridge Careers Service Syndicate and an Honorary Associate of Newnham College.

Arthur is the Commercial Director at Fetch.AI, a two-year-old startup applying AI, machine learning and Blockchain technology. He classes himself as a product manager and product marketing manager and a retired programmer - he has always been much more interested in the business processes underlying the software, rather than the nuts and bolts of its programming. His former positions have included translation engineer, QA tester, change management consultant and project management specialist in the UK, France and the USA. He has an MBA from Cambridge Judge Business School. Whilst at Cambridge, he caught the innovation bug and has been fascinated in new ideas and building new ventures and helping small software companies ever since. He is a co-founder of the Cambridge Product Management Network, a professional network for technology product managers in Cambridge.